First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
Martine J. Piccart-Gebhart
Employment or Leadership Position - PharmaMar (L)
Consultant or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Invivis; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi ; Symphogen; Synthon; Verastem
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Invivis; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi ; Symphogen; Synthon; Verastem
Andrew Peter Holmes
No relevant relationships to disclose
Jose Baselga
No relevant relationships to disclose
Evandro De Azambuja
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Roche
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline; Roche
Amylou C. Dueck
No relevant relationships to disclose
Giuseppe Viale
Consultant or Advisory Role - DAKO; Roche
Honoraria - DAKO; GlaxoSmithKline; Roche
Jo Anne Zujewski
No relevant relationships to disclose
Aron Goldhirsch
No relevant relationships to disclose
Sergio Santillana
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kathleen I. Pritchard
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Expert Testimony - Roche
Antonio C. Wolff
No relevant relationships to disclose
Christian Jackisch
Honoraria - GlaxoSmithKline; Roche
Istvan Lang
No relevant relationships to disclose
Michael Untch
No relevant relationships to disclose
Ian E. Smith
No relevant relationships to disclose
Frances Boyle
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Binghe Xu
No relevant relationships to disclose
Henry Leonidas Gomez
No relevant relationships to disclose
Richard D. Gelber
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose